Advertisement

An elevated C-reactive protein level was associated with cardiovascular events among rheumatoid arthritis patients: What's next?

Published:December 01, 2022DOI:https://doi.org/10.1016/j.ejim.2022.11.032
      Although the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA) is frequently used to estimate cardiovascular risk among rheumatoid arthritis (RA) patients, it does not include plasma C-reactive protein (CRP) concentrations. The study by Erre and colleagues revealed that a 20 mg/L increase in CRP concentrations was correlated with a 1% increase in 10-year cardiovascular risk among RA patients [
      • Erre G.L.
      • Cacciapaglia F.
      • Sakellariou G.
      • et al.
      C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis.
      ]. Their findings suggest that aggressive treatment aimed at reducing inflammation may decrease cardiovascular risks.

      Abbreviations:

      ACPA (anti-cyclic citrullinated peptide antibody), CRP (C-reactive protein), EM (extra-articular manifestation), ERS-RA (Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis), RA (rheumatoid arthritis), SCORE (Systemic Coronary Risk Evaluation)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Erre G.L.
        • Cacciapaglia F.
        • Sakellariou G.
        • et al.
        C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis.
        Eur J Intern Med. 2022; 104: 49-54https://doi.org/10.1016/j.ejim.2022.07.001
        • Ortega-Hernandez O.D.
        • Pineda-Tamayo R.
        • Pardo A.L.
        • et al.
        Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis.
        Clin Rheumatol. 2009; 28: 767-775https://doi.org/10.1007/s10067-009-1145-8
        • Tanasescu C.
        • Jurcut C.
        • Jurcut R.
        • et al.
        Vascular disease in rheumatoid arthritis: from subclinical lesions to cardiovascular risk.
        Eur J Intern Med. 2009; 20: 348-354https://doi.org/10.1016/j.ejim.2008.09.005
        • Arnab B.
        • Biswadip G.
        • Arindam P.
        • et al.
        Anti-CCP antibody in patients with established rheumatoid arthritis: does it predict adverse cardiovascular profile?.
        J Cardiovasc Dis Res. 2013; 4: 102-106https://doi.org/10.1016/j.jcdr.2012.09.003
        • López-Longo F.J.
        • Oliver-Miñarro D.
        • de la Torre I.
        • et al.
        Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis.
        Arthritis Rheumatol. 2009; 61: 419-424https://doi.org/10.1002/art.24390
        • Gómez-Puerta J.A.
        • Sanmartí R.
        Rheumatoid arthritis patients "al nostro cuore".
        Eur J Intern Med. 2022; 96: 46-48https://doi.org/10.1016/j.ejim.2021.12.006
        • Cacciapaglia F.
        • Spinelli F.R.
        • Piga M.
        • et al.
        Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: data from the cardiovascular obesity and rheumatic diSease (CORDIS) study group.
        Eur J Intern Med. 2022; 96: 60-65https://doi.org/10.1016/j.ejim.2021.10.001